TORONTO, Sept. 20, 2019 (GLOBE NEWSWIRE) — MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”), a leader in specialized, research-driven cannabis extraction and cannabinoid isolation, is pleased to announce that its wholly-owned subsidiary, MediPharm Labs Inc., has received Organic Certification from Pro-Cert Organic Systems Ltd. (“Pro-Cert”). Pro-Cert is one of North America’s leading certifiers of organic products and is accredited by IOAS to provide third party certification to the Canadian Organic Standards.
Organic certification is a strong validation of MediPharm Labs’ robust quality management system and GMP compliant facility. This certification further expands the Company’s capabilities to produce bulk wholesale organic extracts and oil for use as an ingredient in finished cannabis concentrate derivatives such as edibles, extracts, topicals and oil products that will be sold in the Company’s wholesale and retail channels for both medical and adult-use markets.
With the increasing demand for high quality, differentiated products, MediPharm Labs has again expanded its capabilities to enable our customers, and other non-cannabis CPG brands, to introduce innovative and premium, higher margin derivative products in additional categories to the Canadian cannabis market.
Pat McCutcheon, CEO of MediPharm Labs
We are proud to receive this certification which further adds third-party validation of our quality management system and integrity in the supply chain. We maintain our commitment to environmental sustainability as we continue to focus on delivering diversified product offerings to enhance the medical- and adult-use consumer experience.
About MediPharm Labs
Founded in 2015, MediPharm Labs specializes in the production of purified, pharmaceutical-like cannabis oil and concentrates and advanced derivative products utilizing a Good Manufacturing Practices designed facility and ISO standard built clean rooms. MediPharm Labs has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with five primary extraction lines having 300,000 kg of annual processing capacity to deliver pure, safe and precisely dosed cannabis products for its customers. Through its wholesale, white label and tolling platforms, they formulate, process, package and distribute cannabis extracts and advanced cannabinoid-based products to domestic and international markets. As a global leader, the Company also completed its first commercial export to Australia in June 2019 and is nearing completion of its Australian extraction facility expected in 2019 with 75,000 kg of annual processing capacity.
For further information, please contact:
Laura Lepore, VP, Investor Relations
Telephone: 705-719-7425 ext 216
Email: investors@medipharmlabs.com
Website: www.medipharmlabs.com
